莫西沙星与左氧氟沙星治疗支原体肺炎疗效及安全性比较

目的比较莫西沙星和左氧氟沙星治疗支原体肺炎的疗效和安全性。方法将支原体肺炎患者71例随机分为两组。治疗组（莫西沙星组）33例给予莫西沙星氯化钠液（拜耳公司）400mg；对照组（左氧氟沙星组）38例给予左氧氟沙星400μg。均每日1次，静脉滴注，疗程10—14d。结果莫西沙星组和左氧氟沙星组的治愈率分别为90．91％和76．32％，有效率分别为96．97％和84．21％，不良反应发生率分别为6．06％和7．89％。结论莫西沙星抗茵活性强，不良反应小，对治疗支原体肺炎安全有效。且优于左氧氟沙星，值得临床推广。

Objective To evaluate the efficacy and safety of moxifloxacin in treatment of mycoplasma pneumonia. Methods A randomized controlled method was used to compare the levofloxacin. The patients with mycoplasma pneumonia were divided into two groups. Grouping method for moxifloxacin for non-agricultural combined medication and higher prices, so in order to obtain informed consent of patients and their families were divided into two groups. Moxifloxacin treatment group of 33 cases, given moxifloxacin sodium chloride solution （Bayer） 400 mg/static point, 38 patients in the control group （levofloxacin group） and given levofloxacin （Yangtze River） 400 mg/day static point, 10 to 14 days of treatment, observe two groups of patients with clinical, X-ray manifestations, Mycoplasma antibodies and adverse reactions. Results The cure group of moxifloxacin and levofloxacin groups were 90.91% and 76.32%. The efficiency was 96.97% and 84.21% respectively. The incidence of adverse reactions was 6.06% and 7.89% respectively. Conclusion Moxifloxacin has strong antibacterial activity, small side effect, safe and effective for the treatment of Mycoplasma pneumonia. It is better than levofloxacin and is worthy of clinical promotion.